Dana-Farber Cancer Institute | Strategic Alliance Partners

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Maxine Sun, PhD, MPH, discusses the association between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape.

Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.

Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Toni K. Choueiri, MD, highlights findings from the CONTACT-03 trial and their clinical significance, as well as the need for continued investigation of PD-1 inhibitor rechallenge despite the negative trial results with cabozantinib and atezolizumab.

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.